News & Insights - Aurevia

Are IVD manufacturers ready for what comes next under IVDR?

Written by Aurevia | 20 Nov 2026

With key IVDR transition deadlines passing, IVD manufacturers need to move from a wait-and-see approach to proactive preparation. 

In her column at Medtech Magazine, Anna-Karin Alm, Head of QARA at Aurevia, emphasizes that manufacturers need to act now. A controlled and documented Quality Management System (QMS), robust technical documentation, and a documented performance evaluation all need to be in place for products intended to remain on the market.

The transition to the EU In Vitro Diagnostic Medical Devices Regulation (IVDR) continues, bringing increased requirements for clinical evidence, technical documentation and quality management. Yet, in her daily work, Anna-Karin sees signs that some IVD manufacturers may still be underestimating the work that lies ahead. 

Key deadlines have already passed

For higher-risk IVDs, important transition deadlines have already passed. For Class D devices, the deadline for having an agreement in place with a Notified Body has long passed. For Class C devices, manufacturers relying on the IVDR transitional provisions needed to have a written agreement with a Notified Body in place by 26 September 2026. 

But meeting these milestones does not mean the work is complete. As Anna-Karin emphasizes in her column, securing an agreement with a Notified Body is not the end goal. It is the starting point for the work that follows.

Manufacturers need to ensure that their QMS and technical documentation are at the required level, including well-documented performance evaluations for the products they intend to keep on the market. Starting improvement activities or bringing in external expertise only shortly before certification activities begin can leave very little room to address gaps. 

Why are some manufacturers still waiting?

In the column, Anna-Karin Alm considers several possible reasons for the industry's cautious approach. Small and medium-sized manufacturers may lack the time, specialist expertise or budget needed for regulatory assessments and updates to quality processes. Short-term business priorities and product development can also compete with regulatory activities for resources. 

Uncertainty around regulatory interpretation and the availability of Notified Bodies may further contribute to a tendency to wait. But delaying preparations carries risks. Products that cannot meet IVDR requirements in time may have to be removed from the market or may not receive certification in time. This could create business setbacks for manufacturers, affect patient safety and disrupt the supply of critical diagnostic tools to healthcare providers. 

From waiting to proactive preparation

The central message is clear: the responsibility remains with manufacturers for ensuring their products are ready for IVDR. Company leadership should make sure regulatory plans are up to date and that the necessary priorities and resources are in place. 

Ultimately, IVDR compliance is about more than meeting regulatory requirements. It is also about helping ensure that diagnostics remain safe, reliable and available when they are needed most.

Read the full article at Medtech Magazine: Anna-Karin Alm: ”Är IVD-tillverkarna redo när det gäller?”

Need support getting your QMS, technical documentation and performance evaluations ready for IVDR?Contact us to learn how Aurevia's quality and regulatory experts can support you.
 
For further reading, browse previous articles from Anna-Karin Alm at Medtech Magazine.